{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T16:37:08Z","timestamp":1795192628227,"version":"4.10.3"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"52","license":[{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,26]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>Hemoptysis is a known complication of lung cancer that may occur after antiplatelet or anticoagulant therapy, chemotherapy, or antiangiogenic agents. Although immune checkpoint inhibitors have improved outcomes in lung cancer, hemoptysis remains a rare but potentially fatal adverse event. We describe an autopsy-confirmed case of complete tumor remission with cavitation leading to fatal hemoptysis after chemoradiotherapy (CRT) followed by combined ipilimumab and nivolumab therapy for squamous cell carcinoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>A 68-year-old man with a history of heavy smoking was found to have a 70-mm right hilar lung lesion and was diagnosed with stage IIIC squamous cell carcinoma with 50% programmed death ligand-1 expression. After CRT and subsequent combination chemotherapy plus immune checkpoint inhibitors, he developed pneumonitis requiring prednisolone (PSL). During PSL tapering, he experienced fever and a new right upper lobe cavitary lesion, which enlarged despite empiric antibiotics. After discharge under apparently stable conditions on a reduced PSL dose, he suddenly developed massive hemoptysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses:<\/jats:title>\n                    <jats:p>The primary diagnosis was stage IIIC squamous cell carcinoma of the lung. During the treatment course, he developed immune checkpoint inhibitor\u2013related pneumonitis and a new cavitary lesion in the right upper lobe. Autopsy revealed a necrotic cavitary lesion with vascular destruction in the right upper lobe, dense adhesions between the lung and chest wall, and no residual carcinoma, infection, or distant metastases, confirming complete tumor remission and fatal hemoptysis due to treatment-related vascular injury.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>The patient received definitive CRT with carboplatin and paclitaxel plus 60 Gy thoracic radiotherapy, followed by carboplatin and paclitaxel combined with ipilimumab and nivolumab, and subsequently maintenance ipilimumab and nivolumab. Immune-related pneumonitis was treated with systemic PSL, which was tapered and subsequently re-escalated when fever and a new cavitary lesion appeared. Empiric broad-spectrum antibiotics were also administered.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>CRT and combined immune checkpoint inhibitor therapy achieved complete tumor remission pathologically. However, the progressive cavitary change in the irradiated lung ultimately resulted in massive hemoptysis, cardiac arrest, and death. Autopsy confirmed a necrotic cavity with vascular destruction without residual malignancy or infection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>In patients receiving ipilimumab and nivolumab after thoracic CRT for centrally located squamous cell carcinoma, rapid tumor necrosis and cavitation within irradiated lung with fragile vasculature may markedly increase the risk of severe and fatal hemoptysis. When initiating or resuming combined immune checkpoint inhibitor therapy in this setting, clinicians should carefully consider CRT-associated vascular fragility and potential immune-mediated vascular injury, and ensure close imaging follow-up and airway surveillance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000046756","type":"journal-article","created":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T21:00:54Z","timestamp":1766782854000},"page":"e46756","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Fatal hemoptysis despite complete remission of squamous cell carcinoma after chemoradiotherapy followed by combined ipilimumab and nivolumab: An autopsy case report"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8352-1877","authenticated-orcid":false,"given":"Kazuhito","family":"Horie","sequence":"first","affiliation":[{"name":"Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan"},{"name":"Department of Respiratory Medicine, Kitasato University Kitasato Institute Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohei","family":"Nakayama","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Kitasato University Kitasato Institute Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiyoshi","family":"Hoshino","sequence":"additional","affiliation":[{"name":"Department of Pathology, Kitasato University Kitasato Institute Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Okada","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Kitasato University Kitasato Institute Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Terai","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan"},{"name":"Keio Cancer Center, Keio University School of Medicine Tokyo, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Kitasato University Kitasato Institute Hospital, Tokyo, Japan"},{"name":"Department of Clinical Medicine (Laboratory of Bioregulatory Medicine), Kitasato University School of Pharmacy, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3122-6937","authenticated-orcid":false,"given":"Takanori","family":"Asakura","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan"},{"name":"Department of Respiratory Medicine, Kitasato University Kitasato Institute Hospital, Tokyo, Japan"},{"name":"Department of Clinical Medicine (Laboratory of Bioregulatory Medicine), Kitasato University School of Pharmacy, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20251226","doi-asserted-by":"crossref","first-page":"299","DOI":"10.5152\/dir.2014.13426","article-title":"Diagnosis and management of hemoptysis.","volume":"20","author":"Larici","year":"2014","journal-title":"Diagn Interv Radiol (Ankara, Turkey)"},{"key":"R2-20251226","doi-asserted-by":"crossref","first-page":"4765","DOI":"10.3390\/cancers15194765","article-title":"Hemoptysis in cancer patients.","volume":"15","author":"Singer","year":"2023","journal-title":"Cancers"},{"key":"R3-20251226","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1200\/JCO.2008.16.2412","article-title":"Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with carboplatin and paclitaxel plus bevacizumab.","volume":"27","author":"Sandler","year":"2009","journal-title":"J Clin Oncol"},{"key":"R4-20251226","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer.","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"key":"R5-20251226","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer.","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol"},{"key":"R6-20251226","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1111\/1759-7714.13578","article-title":"Cavitation and fatal hemoptysis after immunotherapy for advanced lung adenocarcinoma: a case report.","volume":"11","author":"Wang","year":"2020","journal-title":"Thorac Cancer"},{"key":"R7-20251226","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1016\/j.jtho.2017.12.004","article-title":"Massive Hemoptysis after the first administration of pembrolizumab in a strongly positive, centrally located NSCLC.","volume":"13","author":"Artal-Cort\u00e9s","year":"2018","journal-title":"J Thorac Oncol"},{"key":"R8-20251226","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2217\/imt-2018-0136","article-title":"Early fatal hemoptysis after first-dose, first-line pembrolizumab in a central lung cancer: did tumor shrinkage matter?","volume":"11","author":"Facchinetti","year":"2019","journal-title":"Immunotherapy"},{"key":"R9-20251226","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update.","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"R10-20251226","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ejca.2019.05.008","article-title":"Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non\u2013small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial.","volume":"116","author":"Reck","year":"2019","journal-title":"Eur J Cancer"},{"key":"R11-20251226","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jtho.2021.08.019","article-title":"A phase 1 trial of concurrent or sequential ipilimumab, nivolumab, and stereotactic body radiotherapy in patients with stage IV NSCLC study.","volume":"17","author":"Bestvina","year":"2022","journal-title":"J Thorac Oncol"},{"key":"R12-20251226","doi-asserted-by":"crossref","first-page":"100808","DOI":"10.1016\/j.iotech.2024.100808","article-title":"65O CheckMate 73L: phase III study comparing nivolumab (N) + concurrent chemoradiotherapy (CCRT) followed by N \u00b1 ipilimumab (I) v CCRT followed by durvalumab (D) for previously untreated, locally advanced stage (stg) III NSCLC.","volume":"24","author":"Peters","year":"2024","journal-title":"Immuno Oncol Technol"},{"key":"R13-20251226","doi-asserted-by":"crossref","first-page":"e010316","DOI":"10.1136\/jitc-2024-010316","article-title":"Randomized phase II study of consolidation immunotherapy with nivolumab and ipilimumab or nivolumab alone following concurrent chemoradiotherapy for unresectable stage IIIA\/IIIB non-small-cell lung cancer (NSCLC): big ten cancer research consortium LUN16-081.","volume":"13","author":"Durm","year":"2025","journal-title":"J ImmunoTher Cancer"},{"key":"R14-20251226","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41467-022-27960-2","article-title":"Immune-related adverse events and the balancing act of immunotherapy.","volume":"13","author":"Conroy","year":"2022","journal-title":"Nat Commun"},{"issue":"Suppl 7","key":"R15-20251226","doi-asserted-by":"crossref","first-page":"vii59","DOI":"10.1093\/rheumatology\/kez308","article-title":"Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors.","volume":"58","author":"Weinmann","year":"2019","journal-title":"Rheumatology (Oxford, England)"},{"key":"R16-20251226","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1001\/jamaoncol.2022.7711","article-title":"Association of immune-related adverse events with efficacy of atezolizumab in patients with non-small cell lung cancer: pooled analyses of the phase 3 IMpower130, IMpower132, and IMpower150 randomized clinical trials.","volume":"9","author":"Socinski","year":"2023","journal-title":"JAMA Oncol"},{"key":"R17-20251226","doi-asserted-by":"crossref","first-page":"1115305","DOI":"10.3389\/fimmu.2023.1115305","article-title":"Immune checkpoint inhibitors related respiratory disorders in patients with lung cancer: a meta-analysis of randomized controlled trials.","volume":"14","author":"Liu","year":"2023","journal-title":"Front Immunol"},{"key":"R18-20251226","doi-asserted-by":"crossref","first-page":"e2352302","DOI":"10.1001\/jamanetworkopen.2023.52302","article-title":"Immune-related adverse events and survival among patients with metastatic NSCLC treated with immune checkpoint inhibitors.","volume":"7","author":"Cook","year":"2024","journal-title":"JAMA Netw Open"},{"key":"R19-20251226","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer.","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"R20-20251226","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.lungcan.2019.07.027","article-title":"Dynamic changes in PD-L1 expression and CD8+ T cell infiltration in non-small cell lung cancer following chemoradiation therapy.","volume":"136","author":"Choe","year":"2019","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"key":"R21-20251226","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion.","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"R22-20251226","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1183\/09031936.00010114","article-title":"Severe haemoptysis in patients with nonsmall cell lung carcinoma.","volume":"45","author":"Razazi","year":"2015","journal-title":"Eur Respir J"},{"key":"R23-20251226","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1097\/JTO.0b013e3182582912","article-title":"Tumor cavitation in patients with stage III non-small-cell lung cancer undergoing concurrent chemoradiotherapy: incidence and outcomes.","volume":"7","author":"Phernambucq","year":"2012","journal-title":"J Thorac Oncol"},{"key":"R24-20251226","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jacbts.2018.01.014","article-title":"Radiation-induced endothelial vascular injury: a review of possible mechanisms.","volume":"3","author":"Venkatesulu","year":"2018","journal-title":"JACC Basic Transl Sci"},{"key":"R25-20251226","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.chest.2019.03.033","article-title":"Radiation-induced lung injury: assessment and management.","volume":"156","author":"Hanania","year":"2019","journal-title":"Chest"},{"key":"R26-20251226","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1159\/000507848","article-title":"Durvalumab-induced diffuse alveolar hemorrhage: an autopsy case report.","volume":"13","author":"Kanaoka","year":"2020","journal-title":"Case Rep Oncol"},{"key":"R27-20251226","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.19.03158","article-title":"Safety and patient-reported outcomes of atezolizumab plus chemotherapy with or without bevacizumab versus bevacizumab plus chemotherapy in non\u2013small-cell lung cancer.","volume":"38","author":"Reck","year":"2020","journal-title":"J Clin Oncol"},{"key":"R28-20251226","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1084\/jem.20130790","article-title":"RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance.","volume":"211","author":"Xiao","year":"2014","journal-title":"J Exp Med"},{"key":"R29-20251226","doi-asserted-by":"crossref","first-page":"149334","DOI":"10.1016\/j.bbrc.2023.149334","article-title":"Regulatory role of RGMb in lung injury promoted by the combination of carbon ion irradiation and anti-PD-1 antibody through Erk1\/2 and p38 MAPK pathways.","volume":"691","author":"Feng","year":"2024","journal-title":"Biochem Biophys Res Commun"},{"key":"R30-20251226","doi-asserted-by":"crossref","first-page":"152440","DOI":"10.1016\/j.semarthrit.2024.152440","article-title":"A scoping review of vasculitis as an immune-related adverse event from checkpoint inhibitor therapy of cancer: Unraveling the complexities at the intersection of immunology and vascular pathology.","volume":"66","author":"Lee","year":"2024","journal-title":"Semin Arthritis Rheum"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000046756","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:23:53Z","timestamp":1785857033000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000046756"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,26]]},"references-count":30,"journal-issue":{"issue":"52","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000046756","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,26]]},"assertion":[{"value":"2025-07-11","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-17","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}